Callan Family Office LLC Buys New Holdings in Kenvue Inc. $KVUE

Key Points

• Callan Family Office LLC purchased a new stake in Kenvue Inc., acquiring 24,379 shares valued at approximately $510,000 during the second quarter.
• Kenvue reported earnings of $0.29 per share for the last quarter, exceeding estimates, but revenues were down 4.0% year-over-year at $3.84 billion.
• The company recently announced a quarterly dividend increase to $0.2075 per share, representing an annual yield of 5.1% and a payout ratio of 112.16%.

Callan Family Office LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 24,379 shares of the company's stock, valued at approximately $510,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of KVUE. GAMMA Investing LLC raised its position in Kenvue by 33.2% during the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company's stock valued at $594,000 after purchasing an additional 6,169 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Kenvue by 2.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 620,052 shares of the company's stock valued at $14,869,000 after purchasing an additional 16,404 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Kenvue by 154.2% during the 1st quarter. Exchange Traded Concepts LLC now owns 60,130 shares of the company's stock valued at $1,442,000 after purchasing an additional 36,480 shares during the last quarter. Hanson & Doremus Investment Management raised its position in Kenvue by 39.7% during the 1st quarter. Hanson & Doremus Investment Management now owns 3,845 shares of the company's stock valued at $92,000 after purchasing an additional 1,092 shares during the last quarter. Finally, Sowell Financial Services LLC raised its position in Kenvue by 17.6% during the 1st quarter. Sowell Financial Services LLC now owns 12,867 shares of the company's stock valued at $309,000 after purchasing an additional 1,924 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Down 0.3%

KVUE stock opened at $16.18 on Wednesday. Kenvue Inc. has a twelve month low of $15.47 and a twelve month high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market cap of $31.04 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.33 and a beta of 0.72. The business has a 50 day moving average of $18.92 and a 200 day moving average of $21.22.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter last year, the company earned $0.32 EPS. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.1%. Kenvue's dividend payout ratio is 112.16%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Zacks Research raised Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Bank of America decreased their target price on Kenvue from $25.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, October 8th. Rothschild & Co Redburn raised Kenvue from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Redburn Partners set a $22.00 target price on Kenvue in a research report on Friday, September 26th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.